LIONNS-D2 Project - Production of T3S API, IMP and FDF
Estimated value
—
Awarded value
£954k
Suppliers
1
Lots
1
Published
24 Oct 2025
Description
Cardiff University's School of Medicine is procuring the manufacture of a novel investigational medicinal product (IMP), Triiodothyronine sulphate (T3S), for use in a Phase 2b clinical trial. The service includes the production of the active pharmaceutical ingredient (API), the IMP, and the finished drug formulation (FDF) in blister packs. This bespoke drug is intended for hypothyroid patients with a specific genetic variation affecting thyroid hormone metabolism. The supplier will manufacture the product to GMP standards, using a validated Route of Synthesis supported by existing preclinical and toxicology data.
Scope
- Reference
- CU.1623.RR
- Commercial tool
- Standalone contract
Submission & procedure
- Procedure
- Direct award
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£954k
Award date
21 Oct 2025
Contract start
06 Nov 2025
Contract end
31 Jan 2027
Awarded suppliers· 1 supplier
Awarded 21 Oct 2025 · Contract period 06 Nov 2025 — 31 Jan 2027
Other contracts from Cardiff University
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Ardena Holding NV· 1
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| LIONNS-D2 Project – Production of T3S API, IMP and FDF | contract | — | 23 Oct 2025 |